Quality of Life and Social Function in Patients with Schizophrenia or with Bipolar Disorder Receiving Long-acting Antipsychotics

思覺失調症病人或雙相情緒障礙症病人接受長效抗精神病劑的生活品質與社會功能

陳文瑩(Wen-Yin Chen) ； 林式穀(Shih-Ku Lin)

《台灣精神醫學》 31卷4期 (2017/12) Pp. 309-317

摘要

Objective: Long-acting injectable antipsychotics (LAIs) provide a potential solution to overcome poor adherence to oral medications in patients with schizophrenia and bipolar disorder. In this study, we compared variables of subjective experiences and clinical features of patients receiving LAI treatment with schizophrenia and bipolar disorder. Methods: Totally, 449 patients with schizophrenia and 45 patients with bipolar disorder who were regularly on LAI treatment for at least 6 months received the brief version of the World Health Organization Quality of Life (WHOQOL) questionnaire, Subjective Well-being under Neuroleptics scale, Personal and Social Performance scale, Clinical Global Impression of Severity scale, and lack of insight scale. We conducted a retrospective chart review in all patients to determinate the frequency of hospitalizations during their illness course. Results: The frequency of hospitalizations (times/year) was decreased significantly after LAI treatment in patients with schizophrenia (from 0.26 ± 0.42 to 0.12 ± 0.45, p ＜ 0.05) and bipolar disorder (from 0.53 ± 0.65 to 0.16 ± 0.40, p ＜ 0.05). The overall WHOQOL scores and the scores of the four domains were lower than the Taiwanese norm in both groups. Patients with bipolar disorder had significantly higher social domain score than did patients with schizophrenia (p ＜ 0.05). Conclusions: LAI treatment can efficaciously prevent the relapse of patients with schizophrenia or bipolar disorder with poor adherence to medications. Under LAI treatment, patient can keep a certain level of QOL and social function. We recommend LAI treatment as an extensive regiment in patients with poor adherence to oral medications.

關鍵字

quality of life ； social function ； hospitalization ； depot medication

參考文獻

1. Huang YM,Kao CY, Hsu JH, Yu CH: Analyses of the quality of life among patients with schizophrenia. Taiwanese Journal of Psychiatry (Taipei) 2011; 25: 158-66.

2. Kurtz MM, Gerraty RT: A meta-analytic investiga- tion of neurocognitive deficits in bipolar illness: pro- file and effects of clinical state. Neuropsychology 2009; 23: 551-62.

3. Strauss GP, Hong LE, Gold JM, et al.: Factor struc- ture of the Brief Negative Symptom Scale. Schizophr Res 2012; 142: 96-8.

4. Strauss GP, Horan WP, Kirkpatrick B, et al.: Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res 2013; 47: 783-90.

5. Carney MW, Sheffield BF: The long-term mainte- nance treatment of schizophrenic out-patients with depot flupenthixol. Curr Med Res Opin 1973; 1: 423-6.